Skip to main content
SDGR
NASDAQ Life Sciences

Schrodinger's Q1 Report Reveals Strategic Drug Discovery Pivot and Major Validation from Eli Lilly's Ajax Acquisition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$11.98
Mkt Cap
$950.129M
52W Low
$10.945
52W High
$27.63
52W Position info
9.5% above low
Off High info
57% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

SDGR is trading near its 52-week low of $10.945 (9.5% above the low).

Summary

Schrodinger's Q1 report highlights a major validation of its drug discovery platform through Eli Lilly's up to $2.3 billion acquisition of co-founded Ajax Therapeutics, in which Schrodinger holds a 5.8% stake. The company also announced a strategic pivot in its proprietary drug discovery programs to focus on partnerships and achieve $70 million in cost savings, while maintaining strong liquidity.


Key Events · Earnings and Guidance · SDGR

  • Eli Lilly to Acquire Ajax Therapeutics

    Eli Lilly announced the planned acquisition of Ajax Therapeutics, Inc., a company co-founded by Schrodinger, for up to $2.3 billion. Schrodinger held a 5.8% equity position in Ajax as of December 31, 2025, representing a significant validation of its drug discovery platform and investment strategy.

  • Strategic Shift in Drug Discovery Programs

    Schrodinger will cease independent clinical development beyond Phase 1 for its SGR-1505 and SGR-3515 programs, instead seeking strategic partnerships to advance them. This pivot is expected to result in approximately $70 million in cost savings and enhance operational efficiency.

  • Q1 2026 Financial Performance

    Total revenues for Q1 2026 were $58.587 million, a 2% decrease year-over-year. However, drug discovery revenue surged by 124% to $22.879 million, while software products and services revenue decreased by 21% to $35.560 million. Net loss remained stable at $(60.026) million.

  • Strong Liquidity Position

    As of March 31, 2026, the company reported cash, cash equivalents, restricted cash, and marketable securities totaling $406.4 million, which management believes is sufficient to fund operations for at least the next 24 months.


Analysis · SDGR · Life Sciences

Schrodinger's Q1 2026 report is highly significant due to the disclosure of Eli Lilly's planned acquisition of Ajax Therapeutics, a company co-founded by Schrodinger, for up to $2.3 billion. Schrodinger's 5.8% equity stake in Ajax represents a substantial potential return and a strong validation of its physics-based computational platform and strategy of taking equity in collaborators. This news, while previously reported by Reuters, is officially detailed in this filing, providing crucial context. Concurrently, the company announced a strategic shift in its drug discovery segment, ceasing independent clinical development beyond Phase 1 for SGR-1505 and SGR-3515 to focus on partnerships, aiming for $70 million in cost savings. This pivot, combined with strong liquidity of $406.4 million, positions the company to focus on its core platform and early-stage value creation. While overall Q1 revenue saw a slight decrease, the significant growth in drug discovery revenue and stable net loss, alongside the major external validation, paints a largely positive picture for investors.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SDGR was trading at $11.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $950.1M. The 52-week trading range was $10.95 to $27.63. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SDGR - Latest Insights

SDGR
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.50
Real-time Price: $27.79 info
Change: -$1.71 (-6%) info
Market Cap: $2.054B info
SDGR
Nov 04, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.44
Real-time Price: $27.79 info
Change: -$3.65 (-12%) info
Market Cap: $2.054B info
SDGR
Nov 04, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.75
Real-time Price: $27.79 info
Change: -$2.96 (-10%) info
Market Cap: $2.054B info
SDGR
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $28.72
Real-time Price: $27.79 info
Change: -$0.930 (-3%) info
Market Cap: $2.054B info
SDGR
Sep 09, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $20.03
Real-time Price: $27.79 info
Change: +$7.76 (+39%) info
Market Cap: $2.054B info